drugset / Trial / NCT05924152
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
Non-randomizedCrossoverOpen-labelOther
Summary
A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects
Timeline
- Start
- 2023-06-29
- Primary completion
- 2023-08-09
- Completion
- 2023-08-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adagrasib | Small molecule | 400 mg | Oral |
| Comparator | Eltrombopag | Small molecule | 75 mg | Oral |
Indications
No indication recorded.